A Case of Concurrent Leukocytosis and Systemic Capillary Leak Syndrome Due to Pegfilgrastim

Cureus. 2022 May 1;14(5):e24640. doi: 10.7759/cureus.24640. eCollection 2022 May.


Pegfilgrastim is a granulocyte colony-stimulating factor agent used in patients receiving myelosuppressive therapy with chemotherapy or radiation. Two adverse effects associated with this agent include capillary leak syndrome and leukocytosis. To our knowledge, this is the first case of a patient who developed both systemic capillary leak syndrome and leukocytosis greater than 100,000 cells/µL after receiving pegfilgrastim. This patient received early fluid resuscitation, vasopressor support, and methylprednisolone, which improved her clinical course during hospitalization.

Keywords: filgrastim; granulocyte colony-stimulating factor; leukocytosis; neulasta; neupogen; pegfilgrastim; systemic capillary leak syndrome.

Publication types

  • Case Reports